Comparison of the Efficacy of Gabapentin With Loratadine in the Treatment of Uremic Pruritus in Patients of Chronic Kidney Disease.

NCT05750875

01/06/2021

Proforma

Comparison of the efficacy of gabapentin with loratedine in the treatment of uremic pruritus in patients of chronic kidney disease

Patient No.: Visit No.: Date: Group:).:					
Name:				Age/Sex:		
Weight:			Profession			
Residence:			Contact No.:			
<u>Labs:</u>						
CBC: LFTs: RFTs: S/E:	Hb: Bil: Urea: Na:	WBC: ALT: Creat: K:	PLT: AST: Ca:	ALP: PO4	Albumin:	
USG findin	ıgs:					
GFR:			Stage of CKD:			
Undergoin	ng Dialysis: Yes/ N	lo				
Pruritis: Duration: Frequency Severity:	/week:					
No itch					Severe itch	
	1 1	1 1 1	1 1	1 1 1	1	

4 5

7

10

Adverse events:

0 1 2 3

	YES	NO
Drowsiness	ם	ם
Dizziness	ם	۵
Fatigue	ם	۵
Blurred/Double vision	۵	ם
Tremors	ם	۵
Gastro-intestinal symptoms (nausea, vomiting, diarrhea, abdominal pain)	۵	۵
Headache	а	۵
Dry mouth	ם	О
Palpitations	ם	О
Allergic reaction (rash, swelling, wheeze)	О	۵
Any other:		

DERMATOLOGY LIFE QUALITY INDEX (DLQI) Hospital No: Date: Score: Diagnosis: Diagnosis:

The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK. Please tick (\checkmark) one box for each question.

1.	Over the last week, how itchy , sore , painful or stinging has your skin been?	Very much A lot A little Not at all			
2.	Over the last week, how embarrassed or self conscious have you been because of your skin?	Very much A lot A little Not at all			
3.	Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden ?	Very much A lot A little Not at all		Not relevant	
4.	Over the last week, how much has your skin influenced the clothes you wear?	Very much A lot A little Not at all		Not relevant	_
5.	Over the last week, how much has your skin affected any social or leisure activities?	Very much A lot A little Not at all		Not relevant	
6.	Over the last week, how much has your skin made it difficult for you to do any sport ?	Very much A lot A little Not at all		Not relevant	
7.	Over the last week, has your skin prevented you from working or studying?	Yes No		Not relevant	
	If "No", over the last week how much has your skin been a problem at work or studying ?	A lot A little Not at all	0		
8.	Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives ?	Very much A lot A little Not at all		Not relevant	
9.	Over the last week, how much has your skin caused any sexual difficulties?	Very much A lot A little Not at all		Not relevant	
10.	Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time?	Very much A lot A little Not at all		Not relevant	

Please check you have answered EVERY question. Thank you.

[©]AY Finlay, GK Khan, April 1992 www.dermatology.org.uk, this must not be copied without the permission of the authors.

DERMATOLOGY LIFE QUALITY INDEX (DLQI) - INSTRUCTIONS FOR USE

The Dermatology Life Quality Index questionnaire is designed for use in adults, i.e. patients over the age of 16. It is self explanatory and can be simply handed to the patient who is asked to fill it in without the need for detailed explanation. It is usually completed in one or two minutes.

SCORING

The scoring of each question is as follows:

Very much scored 3
A lot scored 2
A little scored 1
Not at all scored 0
Not relevant scored 0
Question 7, 'prevented work or studying' scored 3

The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

HOW TO INTERPRET MEANING OF DLQI SCORES

0-1 no effect at all on patient's life

2-5 small effect on patient's life

6 – 10 moderate effect on patient's life

11 – 20 very large effect on patient's life

21 – 30 extremely large effect on patient's life

REFERENCES

Finlay AY and Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. *Clin Exp Dermatol* 1994; **19:**210-216.

Basra MK, Fenech R, Gatt RM, Salek MS and Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. *Br J Dermatol* 2008; **159**:997-1035.

Hongbo Y, Thomas CL, Harrison MA, Salek MS and Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? *J Invest Dermatol* 2005; **125**:659-64.

There is more information about the DLQI, including over 85 translations, at www.dermatology.org.uk. The DLQI is copyright but may be used without seeking permission by clinicians for routine clinical purposes. For other purposes, please contact the copyright owners.

[©]AY Finlay, GK Khan, April 1992 www.dermatology.org.uk, this must not be copied without the permission of the authors.

PATIENT INFORMED CONSENT

I agree to participate in the study titled:

Comparison of the efficacy of gabapentin with loratadine in the treatment of uremic pruritus in patients of chronic kidney disease.

I have been informed in detail about the study and the possible benefits and side effects of this study. I understand that my participation is voluntary and that I am free to withdraw at any time, without my medical care or legal rights being affected. I allow my doctor or any other person authorized by my doctor to contact me at my home or at an address given by me for treatment and follow up.

I have been assured that the information provided by me will be kept confidential and will be used for research purpose only.

Patient Name:	Witness name:	
CNIC No.:	CNIC No.:	
Signature:	Signature:	
Date:	Date:	
Research	er Signature:	
Date	e:	
CNIC	`No·	